-
Something wrong with this record ?
Recurrent gene mutations detected in canine mast cell tumours by next generation sequencing
M. Vozdova, S. Kubickova, K. Pal, J. Fröhlich, P. Fictum, J. Rubes
Language English Country Great Britain
Document type Journal Article
Grant support
16-26655S
Grantová Agentura České Republiky
LM2015091
Ministerstvo Školství, Mládeže a Tělovýchovy
LQ1601
Ministerstvo Školství, Mládeže a Tělovýchovy
RO 0519
Ministerstvo Zemědělství
PubMed
31999054
DOI
10.1111/vco.12572
Knihovny.cz E-resources
- MeSH
- Mast-Cell Sarcoma genetics pathology veterinary MeSH
- Mast Cells pathology MeSH
- Mutation MeSH
- Dog Diseases genetics pathology MeSH
- GTP-Binding Protein beta Subunits genetics MeSH
- Proto-Oncogene Proteins c-kit genetics MeSH
- Dogs MeSH
- High-Throughput Nucleotide Sequencing veterinary MeSH
- Animals MeSH
- Check Tag
- Dogs MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
Genetic causes of canine mast cell tumours (MCTs), except for mutations in the KIT gene detected in some MCTs, are generally unknown. We used whole exome sequencing to reveal mutation spectra in canine MCTs. We detected somatic mutations in 87 genes including 10 genes recognized as human cancer drivers. Besides KIT, 14 other genes were recurrently mutated. Subsequently, we performed next generation sequencing of a panel of 50 selected genes in additional MCT samples. In this group, the most frequently altered gene was GNB1 showing a recurrent dinucleotide substitution at position of Gly116 in 30% of the MCT samples (n = 6/20) and Ile80 substitution accompanied by a splice region mutation in one case. We extended the study by analysis of the above mentioned GNB1 regions in additional MCT samples by Sanger sequencing, and assessed the overall prevalence of GNB1 mutations to 17.3% (n = 14/81), which is similar to the prevalence of KIT alterations. Our results indicate that GNB1 mutations are probably involved in canine MCT pathogenesis in both cutaneous and subcutaneous MCT cases. As opposed to KIT alterations, the presence of GNB1 mutations did not negatively affect survival times, and our data even showed a trend towards positive prognosis. If our results are confirmed in a larger number of MCTs, an extension of molecular testing of canine MCTs by GNB1 analysis would help to refine the molecular stratification of MCTs, and become useful for targeted treatment strategies.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026404
- 003
- CZ-PrNML
- 005
- 20211026132930.0
- 007
- ta
- 008
- 211013s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/vco.12572 $2 doi
- 035 __
- $a (PubMed)31999054
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Vozdova, Miluse $u Department of Genetics and Reproduction, Central European Institute of Technology, Veterinary Research Institute, Brno, Czech Republic
- 245 10
- $a Recurrent gene mutations detected in canine mast cell tumours by next generation sequencing / $c M. Vozdova, S. Kubickova, K. Pal, J. Fröhlich, P. Fictum, J. Rubes
- 520 9_
- $a Genetic causes of canine mast cell tumours (MCTs), except for mutations in the KIT gene detected in some MCTs, are generally unknown. We used whole exome sequencing to reveal mutation spectra in canine MCTs. We detected somatic mutations in 87 genes including 10 genes recognized as human cancer drivers. Besides KIT, 14 other genes were recurrently mutated. Subsequently, we performed next generation sequencing of a panel of 50 selected genes in additional MCT samples. In this group, the most frequently altered gene was GNB1 showing a recurrent dinucleotide substitution at position of Gly116 in 30% of the MCT samples (n = 6/20) and Ile80 substitution accompanied by a splice region mutation in one case. We extended the study by analysis of the above mentioned GNB1 regions in additional MCT samples by Sanger sequencing, and assessed the overall prevalence of GNB1 mutations to 17.3% (n = 14/81), which is similar to the prevalence of KIT alterations. Our results indicate that GNB1 mutations are probably involved in canine MCT pathogenesis in both cutaneous and subcutaneous MCT cases. As opposed to KIT alterations, the presence of GNB1 mutations did not negatively affect survival times, and our data even showed a trend towards positive prognosis. If our results are confirmed in a larger number of MCTs, an extension of molecular testing of canine MCTs by GNB1 analysis would help to refine the molecular stratification of MCTs, and become useful for targeted treatment strategies.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a nemoci psů $x genetika $x patologie $7 D004283
- 650 _2
- $a psi $7 D004285
- 650 _2
- $a proteiny vázající GTP - beta-podjednotky $x genetika $7 D044387
- 650 _2
- $a vysoce účinné nukleotidové sekvenování $x veterinární $7 D059014
- 650 _2
- $a mastocyty $x patologie $7 D008407
- 650 _2
- $a mastocytární sarkom $x genetika $x patologie $x veterinární $7 D012515
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a protoonkogenní proteiny c-kit $x genetika $7 D019009
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kubickova, Svatava $u Department of Genetics and Reproduction, Central European Institute of Technology, Veterinary Research Institute, Brno, Czech Republic
- 700 1_
- $a Pal, Karol $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Fröhlich, Jan $u Department of Genetics and Reproduction, Central European Institute of Technology, Veterinary Research Institute, Brno, Czech Republic
- 700 1_
- $a Fictum, Petr $u Department of Pathological Morphology and Parasitology, Faculty of Veterinary Medicine, University of Veterinary and Pharmaceutical Sciences Brno, Czech Republic
- 700 1_
- $a Rubes, Jiri $u Department of Genetics and Reproduction, Central European Institute of Technology, Veterinary Research Institute, Brno, Czech Republic
- 773 0_
- $w MED00007703 $t Veterinary and comparative oncology $x 1476-5829 $g Roč. 18, č. 4 (2020), s. 509-518
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31999054 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026132937 $b ABA008
- 999 __
- $a ok $b bmc $g 1715196 $s 1146911
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 18 $c 4 $d 509-518 $e 20200207 $i 1476-5829 $m Veterinary and comparative oncology $n Vet Comp Oncol $x MED00007703
- GRA __
- $a 16-26655S $p Grantová Agentura České Republiky
- GRA __
- $a LM2015091 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- GRA __
- $a LQ1601 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- GRA __
- $a RO 0519 $p Ministerstvo Zemědělství
- LZP __
- $a Pubmed-20211013